• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Mineralys Therapeutics, Inc. - Common Stock (NQ: MLYS )

    12.17 -0.28 (-2.25%)
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 14, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 205,589
    Open 12.45
    Bid (Size) 11.40 (1)
    Ask (Size) 12.88 (1)
    Prev. Close 12.45
    Today's Range 12.08 - 12.83
    52wk Range 5.850 - 16.91
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Earnings Scheduled For November 11, 2024
    Via Benzinga
    Insights into Mineralys Therapeutics's Upcoming Earnings
    Via Benzinga

    Performance

    YTD
    +40.21%
    +40.21%
    1 Month
    -11.17%
    -11.17%
    3 Month
    +24.69%
    +24.69%
    6 Month
    -7.45%
    -7.45%
    1 Year
    +79.50%
    +79.50%

    More News

    Read More
    MLYS INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Mineralys Therapeutics, Inc. and Encourages Investors to Contact the Firm!
    From Bronstein, Gewirtz & Grossman, LLC
    Via Business Wire
    Mineralys Therapeutics Earnings Preview
    Via Benzinga
    Where Mineralys Therapeutics Stands With Analysts
    Via Benzinga
    Where Mineralys Therapeutics Stands With Analysts
    Via Benzinga
    MLYS INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Mineralys Therapeutics, Inc. and Encourages Investors to Contact the Firm!
    From Bronstein, Gewirtz & Grossman, LLC
    Via Business Wire
    MLYS Investors Have Opportunity to Join Mineralys Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
    From Schall Law
    Via GlobeNewswire
    MLYS Stock Earnings: Mineralys Therapeutics Misses EPS for Q2 2024
    Via InvestorPlace
    MLYS Stock Earnings: Mineralys Therapeutics Misses EPS for Q1 2024
    Via InvestorPlace
    MLYS Stock Earnings: Mineralys Therapeutics Beats EPS for Q4 2023
    Via InvestorPlace
    Earnings Scheduled For March 21, 2024
    Via Benzinga
    Why Compass Minerals International Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
    Via Benzinga
    Arm Holdings Posts Upbeat Results, Joins Hershey, CyberArk Software, Wynn Resorts And Other Big Stocks Moving Higher On Thursday
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    12 Health Care Stocks Moving In Thursday's Pre-Market Session
    Via Benzinga
    Why AAR Shares Are Trading Lower By 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session
    Via Benzinga
    Praxis Bioresearch Expands its Board of Directors with Appointment of Adam Levy
    From Praxis Bioresearch, Inc.
    Via GlobeNewswire
    $5M Bet On TreeHouse Foods? Check Out These 3 Stocks Insiders Are Buying
    Via Benzinga
    The Acute Hospital Care Market Is Worth Over $3 Trillion, And Windtree Therapeutics Brings A First-In-Class Drug To An Active Segment Of This Market
    Via Benzinga
    Stocks That Hit 52-Week Lows On Tuesday
    Via Benzinga
    Earnings Scheduled For March 15, 2023
    Via Benzinga
    Benzinga's Top Ratings Upgrades, Downgrades For March 7, 2023
    Via Benzinga
    Around $11M Bet On Insight Enterprises? Check Out These 4 Stocks Insiders Are Buying
    Via Benzinga
    Stocks That Hit 52-Week Lows On Tuesday
    Via Benzinga
    Stocks That Hit 52-Week Lows On Monday
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.